STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Novartis announced that its multiple sclerosis drug, remibrutinib, significantly reduced the occurrence of relapses in patients compared to a standard treatment, according to data presented at a recent conference. The drug was found to lower the annualized relapse rate by 35.2% and 31.2% in two Phase 3 studies, indicating that patients would experience a relapse once every 13 years.
While this efficacy is not as high as that of Roche's rival drug, fenebrutinib, which demonstrated a more than 50% reduction in relapse rates, Novartis' treatment has an advantage in terms of safety, potentially making it a competitive option in the market.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
